Delivering sustainable growth with risk-balanced investment

  • ESTABLISHED IN-MARKET PORTFOLIO AND PROVEN TRACK RECORD

    20 revenue generating in-market assets, including key growth drivers and recurring revenues from seven recently launched inhaled assets.

    (1) Ultibro®, Seebri®, Breezhaler®, AirFluSal® and Forspiro® are registered trademarks of Novartis AG.

    (2) Anoro® Ellipta®, Relvar®/Breo® Ellipta® and Incruse® Ellipta® are registered trade marks of GSK; photos courtesy of GSK. Formulation technology licence – product not developed by Vectura.

  • BROAD LATE -STAGE PIPELINE AND EARLY INNOVATIVE PORTFOLIO

    Balanced pipeline with partnered novel and generic programmes and wholly-owned specialist assets.

    Broad pipeline includes:

  • UNIQUELY POSITIONED

    Proven ability with strong partnerships, licensing agreements and IP portfolio underpin business evolution with exposure to key respiratory growth classes.

    Uniquely integrated inhaled formulation, device and development capabilities.

    Multiple further business development opportunities in dynamic respiratory market.

  • STRONG FINANCIAL DISCIPLINE

    Clear capital allocation priorities to invest for growth and maintain capacity to accelerate strategy.

    Disciplined approach to R&D investment is well aligned to strategy.

    Typical % of total R&D spend:

back to top